A new trading day began on Friday, with Intellia Therapeutics Inc (NASDAQ: NTLA) stock price down -7.61% from the previous day of trading, before settling in for the closing price of $15.12. NTLA’s price has ranged from $13.95 to $34.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 12.09% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 2.01%. With a float of $100.10 million, this company’s outstanding shares have now reached $101.85 million.
In an organization with 526 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 82.41%, operating margin of -1247.99%, and the pretax margin is -1212.19%.
Intellia Therapeutics Inc (NTLA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Intellia Therapeutics Inc is 1.77%, while institutional ownership is 92.42%. The most recent insider transaction that took place on Oct 02 ’24, was worth 38,248. In this transaction VP, Chief Accounting Officer of this company sold 2,012 shares at a rate of $19.01, taking the stock ownership to the 47,012 shares. Before that another transaction happened on Jul 01 ’24, when Company’s EVP, Chief Technical Officer sold 405 for $22.93, making the entire transaction worth $9,287. This insider now owns 71,470 shares in total.
Intellia Therapeutics Inc (NTLA) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -1.46 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.00% during the next five years compared to -22.30% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Here are Intellia Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.45, a number that is poised to hit -1.35 in the next quarter and is forecasted to reach -5.47 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Let’s dig in a bit further. During the last 5-days, its volume was 2.63 million. That was better than the volume of 1.68 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 24.25%. Additionally, its Average True Range was 1.16.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 0.14%, which indicates a significant decrease from 0.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.83% in the past 14 days, which was higher than the 65.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.64, while its 200-day Moving Average is $23.35. However, in the short run, Intellia Therapeutics Inc’s stock first resistance to watch stands at $14.87. Second resistance stands at $15.77. The third major resistance level sits at $16.22. If the price goes on to break the first support level at $13.51, it is likely to go to the next support level at $13.06. Assuming the price breaks the second support level, the third support level stands at $12.16.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
With a market capitalization of 1.31 billion, the company has a total of 101,849K Shares Outstanding. Currently, annual sales are 36,280 K while annual income is -481,190 K. The company’s previous quarter sales were 9,110 K while its latest quarter income was -135,710 K.
